Effect of Isorhamnetin on Inhibition of RANKL-induced Osteoclast Differentiation

The elderly population is increasing worldwide. Osteoporosis, one of the diseases of the elderly, is a disease that occurs due to a decrease in bone density or changes in bone structure and strength. Osteoporosis mainly occurs in postmenopausal women and the elderly. In the treatment of osteoporosis, it is important to prevent bone loss and inhibit the formation of osteoclasts, which are involved in bone resorption. Research is needed to prevent and treat fractures caused by osteoporosis. In this study, we investigated the effect of isorhamnetin on RANKL-induced osteoclast differentiation. Isorhamnetin significantly inhibited osteoclast differentiation by effectively inhibiting transcription and translation of NFATc1, an essential component in the osteoclast differentiation process. Additionally, the mRNA expression of TRAP, DC-STAMP, and CTSK, genes related to osteoclast differentiation, was suppressed. Therefore, isorhamnetin has the potential to be used as a functional food and therapeutic agent for the treatment of osteoporosis.